Prot #CMEK162AUS11: Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors

Project: Research project

Project Details

StatusFinished
Effective start/end date11/14/13 → 11/14/16

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CMEK162AUS11)